Merck's Keytruda Secures Pivotal FDA Approval in Colorectal Cancer, Reinforcing Oncology Dominance

In a move that underscores the enduring strength of immuno-oncology therapies, Merck & Co. (NYSE: MRK) revealed on March 5, 2026, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Keytruda (pembrolizumab) in combination with standard chemotherapy for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. This approval, based on data from the Phase 3 KEYNOTE-177 trial and supportive studies, positions Keytruda as a cornerstone in addressing one of the most challenging subsets of gastrointestinal cancers, which affect approximately 15% of colorectal cancer cases.

Clinical Trial Data and Approval Rationale

The FDA's decision hinges on compelling efficacy results from the KEYNOTE-651 trial, where Keytruda plus chemotherapy demonstrated a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy alone. Specifically, the combination regimen achieved a median PFS of 16.5 months versus 8.2 months for chemotherapy monotherapy, representing a 52% reduction in the risk of disease progression or death (hazard ratio [HR] 0.48; 95% CI, 0.35-0.64; p<0.0001). Objective response rates (ORR) were markedly higher at 54% for the Keytruda arm compared to 29% in the control group, with durable responses observed in 42% of responders lasting at least 12 months.

These outcomes build on Keytruda's established profile in MSI-H/dMMR tumors across multiple indications, where it has consistently shown superior efficacy due to its PD-1 inhibition mechanism that unleashes the immune system's anti-tumor response. Colorectal cancer remains a leading cause of cancer-related mortality in the U.S., with over 153,000 new cases diagnosed annually according to American Cancer Society data. The MSI-H/dMMR subtype, while responsive to immunotherapy, has limited first-line options, making this approval a game-changer for patients facing aggressive disease.

Market Reaction and Stock Performance

Merck's shares reacted swiftly to the news, climbing 4.2% in after-hours trading on March 5 to close around $132.50, extending a year-to-date gain of 12%. The stock has outperformed the S&P 500 Health Care Index by 8 percentage points over the past six months, buoyed by Keytruda's relentless label expansions. Trading volume spiked to 2.3 million shares in the extended session, well above the average of 1.1 million, indicating strong institutional interest.

Keytruda, Merck's crown jewel, generated $25.8 billion in global sales for 2025, accounting for 42% of the company's total revenue and growing 19% year-over-year despite looming patent expiry in 2028. Analysts project this new indication could add $1.2 billion in peak annual sales by 2030, per consensus estimates from Bloomberg Intelligence, helping to mitigate biosimilar risks. Merck's forward P/E ratio of 14.5x remains attractive relative to biotech peers averaging 18x, supporting a bullish outlook.

Strategic Implications for Merck and the Biotech Sector

This approval arrives at a critical juncture for Merck, which has aggressively diversified Keytruda's label to over 40 indications since its initial 2014 lung cancer nod. Oncology now comprises 65% of Merck's pipeline, with 28 late-stage programs, including next-generation candidates like MK-1084, a next-gen PD-1/VEGF bispecific entering Phase 3. The company's $12 billion in cash reserves and a robust balance sheet (net debt-to-EBITDA of 1.2x) enable continued M&A, as evidenced by the recent $2.5 billion acquisition of biotech firm EyeBio in late 2025.

For the broader biotechnology sector, the news reinforces the viability of PD-1 inhibitors in solid tumors. Competitors such as Bristol Myers Squibb (BMY) with Opdivo and Regeneron (REGN) with Libtayo face heightened pressure, though their respective market shares in colorectal cancer remain modest at under 10%. The XBI Biotech ETF rose 1.8% on the day, with oncology-focused names like Exelixis (EXEL) and Incyte (INCY) gaining 2-3%, suggesting sector-wide tailwinds.

Competitive Landscape and Patent Considerations

The immuno-oncology market, valued at $48 billion globally in 2025, is projected to reach $72 billion by 2030 (Statista). Keytruda commands a 35% share, dwarfing Opdivo's 25%. However, patent cliffs loom: Keytruda's core composition-of-matter patent expires in 2028, potentially opening doors to biosimilars from Samsung Bioepis and Organon. Merck counters this with subcutaneous formulations and combination strategies, including recent data from KEYNOTE-859 showing benefits in HER2-negative gastric cancer.

• Key Metrics: Keytruda 2025 sales: $25.8B (+19% YoY)

• Colorectal cancer market size: $8.5B (2025 est.)

• Projected incremental sales from new indication: $1.2B peak

• Merck Q4 2025 EPS: $2.15 (beat by 8%)

Regulatory tailwinds persist, with the FDA's Oncology Center of Excellence fast-tracking reviews. Merck's next catalysts include Phase 3 readouts in 2026 for Keytruda in adjuvant melanoma and NSCLC maintenance.

Risk Factors and Forward Outlook

Despite the positives, risks abound. Clinical trial failures, such as the recent KEYNOTE-028 miss in pancreatic cancer, highlight oncology's high attrition rates (85% Phase 3 failure rate per BIO data). Macro pressures, including potential U.S. drug pricing reforms under the Inflation Reduction Act extensions, could cap upside. Merck's exposure to China (20% of Keytruda sales) adds geopolitical volatility amid ongoing trade tensions.

Analyst consensus remains bullish, with 22 Buy ratings and an average price target of $148 (12% upside) from firms like Jefferies and Piper Sandler. Longer-term, Merck's pivot to ADCs and radiopharma positions it for the next wave, with subcutaneous Keytruda Phase 3 data expected mid-2026.

Investment Thesis

Merck exemplifies resilient biotech leadership, with Keytruda's expansion validating a buy-and-hold strategy. At current valuations, MRK offers defensive growth with a 2.8% dividend yield and 15% EPS CAGR through 2030. Investors should monitor upcoming earnings on April 29, 2026, for updated guidance incorporating this approval. In a sector prone to volatility, Merck's data-driven execution provides a compelling risk-reward profile, meriting overweight allocation in healthcare portfolios.

This development not only bolsters Merck's franchise but signals sustained innovation in biotechnology, fostering optimism for shareholders and patients alike.